We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
Read MoreHide Full Article
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $24.06, marking a -9.75% move from the previous day. The stock's change was less than the S&P 500's daily loss of 4.36%. Meanwhile, the Dow lost 3.44%, and the Nasdaq, a tech-heavy index, lost 5.52%.
Shares of the company have depreciated by 9.75% over the course of the past month, underperforming the Medical sector's gain of 12.63%, and the S&P 500's loss of 0.38%.
The investment community will be closely monitoring the performance of Hims & Hers Health, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on November 9, 2026. The company is expected to report EPS of $0.07, up 16.67% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $893.37 million, indicating a 49.15% growth compared to the corresponding quarter of the prior year.
HIMS's full-year Zacks Consensus Estimates are calling for earnings of -$0.79 per share and revenue of $3.22 billion. These results would represent year-over-year changes of -249.06% and +37.03%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for Hims & Hers Health, Inc. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Hims & Hers Health, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 89, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
In the latest trading session, Hims & Hers Health, Inc. (HIMS - Free Report) closed at $24.06, marking a -9.75% move from the previous day. The stock's change was less than the S&P 500's daily loss of 4.36%. Meanwhile, the Dow lost 3.44%, and the Nasdaq, a tech-heavy index, lost 5.52%.
Shares of the company have depreciated by 9.75% over the course of the past month, underperforming the Medical sector's gain of 12.63%, and the S&P 500's loss of 0.38%.
The investment community will be closely monitoring the performance of Hims & Hers Health, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on November 9, 2026. The company is expected to report EPS of $0.07, up 16.67% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $893.37 million, indicating a 49.15% growth compared to the corresponding quarter of the prior year.
HIMS's full-year Zacks Consensus Estimates are calling for earnings of -$0.79 per share and revenue of $3.22 billion. These results would represent year-over-year changes of -249.06% and +37.03%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for Hims & Hers Health, Inc. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Hims & Hers Health, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 89, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.